Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 8INDUSTRY 3OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 1Stomach Neoplasms 1Sarcopenia 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Esophageal Squamous Cell Carcinoma 1Efficacy, Team 1Colorectal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Irinotecan 11Oxaliplatin 8Cetuximab 7Fluorouracil 6Leucovorin 5Bevacizumab 5Standard of Care 4S 1 (combination) 4Capecitabine 4trifluridine tipiracil drug combination 2tislelizumab 2apatinib 2Propranolol 2Preoperative Exercise 2Panitumumab 2Levoleucovorin 2Folfox protocol 2Etodolac 2Endoscopic Mucosal Resection 2Drug Therapy 2Chemotherapy, Adjuvant 2trebananib 1regorafenib 1envafolimab 1Trifluridine 1Thalidomide 1Surveys and Questionnaires 1Occult Blood 1Neoadjuvant Therapy 1Moxibustion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Colorectal Neoplasms × Immune Checkpoint Inhibitors × Clear all
NCT06321081 2024-03-20

ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC

Beijing Hospital

Phase 2 Recruiting
60 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡